Description: Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (beta5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (beta1) and trypsin-like (beta2) proteolytic sites...

Synthetic. Chemical. CAS: 1072833-77-2. Formula: C14H19BCl2N2O4. MW: 361. Synthetic. Potent selective and reversible proteasome inhibitor (all proteolytic subunits). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.4nM). Cross-reacts and inhibits the trypsin-like beta2 subunit...

MLN-2238 is a proteasome inhibitor that modulates miR33b, a tumor suppressor microRNA. MLN-2238 exhibits anticancer activity, downregulating Pim-1 activity in multiple myeloma cells.

MLN2238 is an inhibitor of the beta5 subunit of the 20S proteasome (IC50 = 3.4 nM in a cell-free assay) and an active metabolite of MLN9708 (Cay-18386). It is formed from MLN9708 via hydrolysis in plasma. MLN2238 is selective for the chymotrypsin-like beta5 subunit over the caspase-like beta1 and trypsin-like beta2...